Sort   by:  
 Page size 
UnknownRecent Advances in Prostate Cancer Treatment and Drug Discovery.
Not available
S-EPMC5983695 | biostudies-literature
UnknownGenome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Not available
S-EPMC4536071 | biostudies-literature
UnknownDarolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
Not available
S-EPMC7463324 | biostudies-literature
UnknownComparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition.
Not available
S-EPMC9817687 | biostudies-literature
UnknownFunctional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Not available
S-EPMC6599250 | biostudies-literature
UnknownTargeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion.
Not available
S-EPMC10148872 | biostudies-literature
UnknownDarolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Not available
S-EPMC6766977 | biostudies-literature
Unknown(1)H NMR-based metabolic profiling of urinary tract infection: combining multiple statistical models and clinical data.
Not available
S-EPMC3483096 | biostudies-literature
UnknownmTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.
Not available
S-EPMC5078062 | biostudies-literature
GenomicsChIP-Seq for RIP140, using the human breast cancer cell line MCF-7 in the absence of hormone or after treatment with Estradiol
This experiment is designed to assess the role of RIP140 in estrogen receptor-dependent gene expression in MCF7 luminal breast cancer cells. Hormone deprived MCF7 cells were treated for 3 hours with E2 or DMSO control, after which samples were processed for ChIp-seq for RIp140.
ORGANISM(S): Homo sapiens 
2015-03-16 | E-MTAB-2576 | biostudies-arrayexpress
Sort   by:  
 Page size